Close Menu

Precision Oncology News: Breaking News

The funding will be used to complete enrollment for a Phase II study evaluating Elevation's lead product candidate seribantumab.

The deal joins Indivumed's collection of tissue biospecimens and immunohistochemistry expertise with Ultivue's multiplex immunofluorescence platform.

The companies aim to create new products enabling faster access to predictive information used in treatment planning for patients with breast cancer.

The studies will evaluate Lorbrena in patients with newly diagnosed, high-risk neuroblastoma whose tumors harbor an ALK gene mutation.

The new consortium is aiming to make comprehensive genomic profiling accessible to advanced cancer patients in the US, to help inform their treatment decisions.

The B44 supertype is associated with improved survival in melanoma patients treated with immunotherapy, but less so in NSCLC patients, due to mutational differences.

The company has used its semi-closed electroporation system to manufacture autologous CAR T cells to treat ovarian cancer and leukemia patients in two trials.

A deal with Burning Rock will allow the test to be used in trials and clinics in China, and Myriad will license its technology to French and German pathology labs.

The agency approved Agilent/Dako's PD-L1 IHC test for identifying TNBC patients who are most likely to respond to Keytruda and chemo.

The firm is still designing the study, which will explore the ability of GP2 to prevent recurrence in HER2-postive breast cancer after surgery. 

The Phase I trial will assess BBP-398's safety and anti-tumor activity in cancers with MAPK signaling pathway genetic mutations, including mutations in RAS genes.

Using OneThree's AI platform, Jubilant has identified biomarker-defined cancer indications that it hopes to pursue for JBI-802 in human trials next year.

The company fully enrolled a Phase III trial in which patients with DGM1-positive, diffuse large B-cell lymphoma received enzastaurin plus chemo or chemo alone.

In the Phase II trial, FGFR2b-positive gastric cancer patients on bemarituzumab and chemo had better response rates and survival than those just on chemo.

In the wake of encouraging interim results, Moderna plans to expand the head and neck cancer cohort of its mRNA-4157 plus Keytruda clinical trial.

In a non-exclusive deal, GlaxoSmithKline will use Adaptive Biotechnology's NGS-based ClonoSeq test to assess MRD across its hematology portfolio.

The agency recommended the combination for previously untreated CLL patients with certain genetic mutations, including those with a 17p deletion or TP53 mutation.

Baiyunshan will assume responsibility for developing and commercializing HG030 in mainland China, while HitGen will retain rights in all other territories.

The partners will apply whole-exome and whole-transcriptome analysis to evaluate two existing drugs for squamous cell carcinoma treatment.

The company decided this after the Keytruda-Yervoy combination did not improve overall survival or progression-free survival compared to Keytruda monotherapy.

The company's T-cell product, PRIME IL-15, which is loaded with an IL-15fc nanogel, led 10 out of 17 advanced solid tumor patients to have stable disease.

The test will use a blood-based biopsy to detect patients with BRCA1, BRCA2, and/or ATM alterations in metastatic castration-resistant prostate cancer.

The combination treatment was approved for metastatic NSCLC patients without EGFR or ALK gene mutations and regardless of their PD-L1 status.

The company will continue to evaluate several agents, including its c-MET inhibitor APL-101 for patients with a variety of MET dysregulated solid cancers.

The researchers said their findings could explain improved outcomes of sarcomatoid tumors to checkpoint blockade versus antiangiogenic therapies alone.